You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA-CA19 CAR

Showing 1 - 25 of 1,436
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)

Enrolling by invitation
  • Multiple Myeloma
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
  • London, County (optional), United Kingdom
    University College London Hospital
Sep 15, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia Trial in Hangzhou (CD19/BCMA CAR T-cells)

Recruiting
  • POEMS Syndrome
  • +3 more
  • CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 21, 2022

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Scleroderma, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Scleroderma
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Sjogren's Syndrome, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Sjogren's Syndrome
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Immune Nephritis, Autoimmune Diseases, Lupus Nephritis Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Immune Nephritis
  • +2 more
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jul 23, 2022

Platelet Transfusion Refractoriness, Acute Leukemia in Remission Trial in Suzhou (CAR-T infusion)

Recruiting
  • Platelet Transfusion Refractoriness
  • Acute Leukemia in Remission
  • CAR-T infusion
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 19, 2021

Systemic Lupus Erythematosus, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Aug 31, 2021

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jun 13, 2021

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

B-cell Lymphoma Trial (Fast Dual CAR-T Injection)

Not yet recruiting
  • B-cell Lymphoma
  • Fast Dual CAR-T Injection
  • (no location specified)
May 7, 2021

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Multiple Myeloma Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Multiple Myeloma
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse Trial in Hangzhou (CD19/BCMA

Recruiting
  • Multiple Myeloma in Relapse
  • +5 more
  • CD19/BCMA Targeted CAR T-cells and dasatinib
  • CD19/BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Oct 27, 2020

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

B Cell Lymphoma, B Cell Leukemia, Myeloma Trial in Wenzhou (CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell)

Active, not recruiting
  • B Cell Lymphoma
  • +5 more
  • CAR-CD19 T cell
  • +5 more
  • Wenzhou, Zhejiang, China
    First Affiliated Hospital of Wenzhou Medical University
Oct 5, 2020

Acute Lymphocytic Leukemia, B-Cell Trial in Taiyuan (CD19-CD22 CAR-T cells)

Recruiting
  • Acute Lymphocytic Leukemia， B-Cell
  • CD19-CD22 CAR-T cells
  • Taiyuan, Shanxi, China
    Hematology Department of ShanXi Cancer Hospital
Jan 17, 2021

Multiple Myeloma Trial in Sanhe (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Not yet recruiting
  • Multiple Myeloma
  • BCMA/CD19 dual-target CAR-T cell immunotherapy
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jun 1, 2020